CMP Pharma Inc drugs
7 results
Atorvaliq (atorvaliq)
(ATORVALIQ)CMP Pharma Inc
Usage: ATORVALIQ is indicated for reducing cardiovascular risk in adults with or without clinically evident coronary heart disease (CHD), and for lowering LDL cholesterol in adults and pediatric patients with primary hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia, and other lipid disorders.
Carospir (carospir)
(CaroSpir)CMP Pharma Inc
Usage: CAROSPIR is indicated for treating NYHA Class III-IV heart failure with reduced ejection fraction, managing hypertension as an add-on therapy, and managing edema in adult cirrhotic patients unresponsive to fluid and sodium restriction. It aids survival, edema management, and reducing hospitalization for heart failure.
Liqrev (sildenafil)
(sildenafil)CMP Pharma Inc
Usage: LIQREV is indicated for adults with pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity and delay clinical worsening. Pediatric use information exists for a related drug, REVATIO, but is not included for LIQREV due to marketing exclusivity.
Norliqva (amlodipine)
(amlodipine)CMP Pharma Inc
Usage: NORLIQVA® is indicated for treating hypertension in adults and children 6 years and older to lower blood pressure and reduce cardiovascular event risks. It also treats chronic stable angina, vasospastic angina, and reduces hospitalization risk in patients with documented coronary artery disease.
Oracit (citric acid and sodium citrate)
(Citric Acid and Sodium Citrate)CMP Pharma Inc
Usage: ORACIT® is indicated for treating metabolic acidosis, maintaining alkaline urine in conditions like uric acid and cystine calculi, and addressing acidosis in specific renal tubular disorders.
Tadliq (tadalafil)
(Tadalafil)CMP Pharma Inc
Usage: TADLIQ® is indicated for treating pulmonary arterial hypertension (PAH) to improve exercise ability, primarily in patients with NYHA Functional Class II-III symptoms, including idiopathic, heritable PAH, and PAH related to connective tissue diseases.
Zimhi (naloxone hydrochloride)
(Naloxone Hydrochloride)CMP Pharma Inc
Usage: ZIMHI is indicated for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients, characterized by respiratory and/or central nervous system depression. It is intended for immediate use in settings where opioids are present but is not a substitute for emergency medical care.